Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001764013-25-000082
Filing Date
2025-04-25
Accepted
2025-04-25 16:15:56
Documents
2
Period of Report
2025-04-23

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1745612149.html 4  
1 FORM 4 wk-form4_1745612149.xml 4 3845
2 EX-24 imvt-edgarpowerofattorneyx.htm EX-24 7897
  Complete submission text file 0001764013-25-000082.txt   13280
Mailing Address 320 WEST 37TH STREET NEW YORK NY 10018
Business Address 320 WEST 37TH STREET NEW YORK NY 10018 917-580-3099
Immunovant, Inc. (Issuer) CIK: 0001764013 (see all company filings)

EIN.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O IMMUNOVANT, INC. 320 WEST 37TH STREET NEW YORK NY 10018
Business Address
Geffner Michael (Reporting) CIK: 0002007249 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38906 | Film No.: 25874269